50 research outputs found
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΉ ΠΌΠΎΡΠΎΡΠ½ΠΎΠΉ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΠΈ Ρ Π±Π»ΠΎΠΊΠ°ΠΌΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ Π΄Π²ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ»ΡΡΠ°Π΅Π²
Introduction. The heterogeneity of the forms and severity of Guillain-Barre syndrome explains the variability of recovery: from rapid and complete (in most cases) to slow with the development of persistent residual deficiency (rarely). It is unclear how effective the Erasmus GuillainβBarre syndrome Outcome Scores and its modified version are for different forms of the disease.The aim of the study β to demonstrate the features of recovery in acute motor axonal neuropathy with conduction blocks on the example of 2 clinical cases; to show the possibilities of Erasmus GuillainβBarre syndrome Outcome Scores and its modified version in predicting recovery in this form of the disease.Materials and methods. Data from 2 patients with acute motor axonal neuropathy with motor conduction blocks were retrospectively analyzed. Calculation of the score and assessment of the prognosis of walking recovery by 6 months from the onset of the disease were performed using the online calculator International Guillain-Barre syndrome Outcome Study Prognosis tool in the acute period.Results. In both patients, the forecast of recovery of walking by half a year from the onset of the disease on the Erasmus GuillainβBarre syndrome Outcome Scores and modified Erasmus GuillainβBarre syndrome Outcome Scores scales in the acute period was erroneous. In the first case, the total score on the Erasmus GuillainβBarre syndrome Outcome Scores and its modification in the acute period was 5 and 10 points respectively (poor prognosis), which foreshadowed a long rehabilitation process and incomplete recovery. However, the regression of disorders was dramatic and complete, and by the second month of the disease, only minimal motor disorders remained. In the second patient, on the contrary, the total Erasmus GuillainβBarre syndrome Outcome Scores and its modification during the period of increasing symptoms was 3 and 7 points respectively (good prognosis), while recovery was delayed β only by 5 months from the onset of the disease, the ability to move with support was restored.Conclusion. The GuillainβBarre syndrome is a disease with a favorable prognosis for recovery. However, the prediction of regression of motor disorders should be approached carefully, because in some cases, generally accepted criteria and prognostic scales may not work. Acute motor axonal neuropathy with conduction blocks is a unique form of the disease that has pathophysiological and clinical-neurophysiological features, which should be taken into account when managing this category of patients.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΡΠΎΡΠΌ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½Π΅ΠΉ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°Π΅Ρ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΡ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ: ΠΎΡ Π±ΡΡΡΡΠΎΠ³ΠΎ ΠΈ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ (Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π²) Π΄ΠΎ ΠΊΡΠ°ΠΉΠ½Π΅ Π·Π°ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ³ΠΎ, Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠΉΠΊΠΎΠ³ΠΎ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΡΠΈΡΠΈΡΠ° (ΡΠ΅Π΄ΠΊΠΎ). ΠΡΡΠ°Π΅ΡΡΡ Π½Π΅ΡΡΠ½ΡΠΌ Π²ΠΎΠΏΡΠΎΡ, Π½Π°ΡΠΊΠΎΠ»ΡΠΊΠΎ ΡΠΊΠ°Π»Π° ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΡΠ°ΡΠΌΡΡ ΠΈ Π΅Π΅ ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π²Π΅ΡΡΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΠΈΠΌΡ ΠΊΠΎ Π²ΡΠ΅ΠΌ ΡΠΎΡΠΌΠ°ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ 2 ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»ΡΡΠ°Π΅Π² ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΉ ΠΌΠΎΡΠΎΡΠ½ΠΎΠΉ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΠΈ Ρ Π±Π»ΠΎΠΊΠ°ΠΌΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ; ΠΏΠΎΠΊΠ°Π·Π°ΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠΊΠ°Π»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°ΠΠ°ΡΡΠ΅ ΠΡΠ°ΡΠΌΡΡ ΠΈ Π΅Π΅ ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π²Π΅ΡΡΠΈΠΈ Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ 2 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΠΎΡΡΡΠΎΠΉ ΠΌΠΎΡΠΎΡΠ½ΠΎΠΉ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ Ρ ΠΌΠΎΡΠΎΡΠ½ΡΠΌΠΈ Π±Π»ΠΎΠΊΠ°ΠΌΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ. Π Π°ΡΡΠ΅Ρ Π±Π°Π»Π»ΠΎΠ² ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Ρ
ΠΎΠ΄ΡΠ±Ρ ΠΊ 6 ΠΌΠ΅Ρ ΠΎΡ Π½Π°ΡΠ°Π»Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΎΠ½Π»Π°ΠΉΠ½-ΠΊΠ°Π»ΡΠΊΡΠ»ΡΡΠΎΡΠ° International GuillainβBarre syndrome Outcome Study Prognosis tool Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΎΠ±Π΅ΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΠΏΡΠΎΠ³Π½ΠΎΠ· Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Ρ
ΠΎΠ΄ΡΠ±Ρ ΠΊ ΠΏΠΎΠ»ΡΠ³ΠΎΠ΄Ρ ΠΎΡ Π½Π°ΡΠ°Π»Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠΎ ΡΠΊΠ°Π»Π°ΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΈ Π΅Π΅ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΎΠΊΠ°Π·Π°Π»ΡΡ ΠΎΡΠΈΠ±ΠΎΡΠ½ΡΠΌ. Π ΠΏΠ΅ΡΠ²ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅ ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΡΠ°ΡΠΌΡΡ ΠΈ Π΅Π΅ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5 ΠΈ 10 Π±Π°Π»Π»ΠΎΠ² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (ΠΏΠ»ΠΎΡ
ΠΎΠΉ ΠΏΡΠΎΠ³Π½ΠΎΠ·), ΡΡΠΎ ΠΏΡΠ΅Π΄Π²Π΅ΡΠ°Π»ΠΎ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΈ Π½Π΅ΠΏΠΎΠ»Π½ΠΎΠ΅ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅. ΠΠ΄Π½Π°ΠΊΠΎ ΡΠ΅Π³ΡΠ΅ΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π±ΡΠ» Π΄ΡΠ°ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΠΏΠΎΠ»Π½ΡΠΌ, ΠΈ ΡΠΆΠ΅ ΠΊΠΎ 2-ΠΌΡ ΠΌΠ΅ΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠΎΡ
ΡΠ°Π½ΡΠ»ΠΈΡΡ Π»ΠΈΡΡ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΠ΅ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ. Π£ 2-ΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ, Π½Π°ΠΏΡΠΎΡΠΈΠ², ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΡΠ°ΡΠΌΡΡ ΠΈ Π΅Π΅ ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ Π±ΡΠ»Π° ΡΠ°Π²Π½Π° 3 ΠΈ 7 Π±Π°Π»Π»Π°ΠΌ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (Ρ
ΠΎΡΠΎΡΠΈΠΉ ΠΏΡΠΎΠ³Π½ΠΎΠ·), ΠΏΡΠΈ ΡΡΠΎΠΌ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΡΠΌ β ΡΠΎΠ»ΡΠΊΠΎ ΠΊ 5-ΠΌΡ ΠΌΠ΅ΡΡΡΡ ΠΎΡ Π½Π°ΡΠ°Π»Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²ΠΈΠ»Π°ΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ Ρ ΠΎΠΏΠΎΡΠΎΠΉ.ΠΡΠ²ΠΎΠ΄Ρ. Π‘ΠΈΠ½Π΄ΡΠΎΠΌ ΠΠΈΠ΅ΠΉΠ½Π°βΠΠ°ΡΡΠ΅, Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ Ρ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΊ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ΅Π½Π°ΡΠΈΡ ΡΠ΅Π³ΡΠ΅ΡΡΠ° Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΈΡΡ ΠΎΡΡΠΎΡΠΎΠΆΠ½ΠΎ, ΡΠ°ΠΊ ΠΊΠ°ΠΊ Π² ΡΡΠ΄Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠ±ΡΠ΅ΠΏΡΠΈΠ½ΡΡΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΊΠ°Π»Ρ ΠΌΠΎΠ³ΡΡ Π½Π΅ ΡΠ°Π±ΠΎΡΠ°ΡΡ. ΠΡΡΡΠ°Ρ ΠΌΠΎΡΠΎΡΠ½Π°Ρ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΡ Ρ Π±Π»ΠΎΠΊΠ°ΠΌΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ β ΡΠ½ΠΈΠΊΠ°Π»ΡΠ½Π°Ρ ΡΠΎΡΠΌΠ° Π±ΠΎΠ»Π΅Π·Π½ΠΈ, ΠΈΠΌΠ΅ΡΡΠ°Ρ ΠΏΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ, ΡΡΠΎ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ Π²Π΅Π΄Π΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
Transthyretin amyloidosis (ATTR-amyloidosis) is a systemic progressive fatal disease, for which a modifying therapy has recently been proposed that delays the progression of the disease and improves the patientβs quality of life. The delay in the diagnosis of ATTR-amyloidosis is associated with the heterogeneity of the manifestations of the disease, as well as insufficient awareness of doctors of different specialties about the disease. A review of recent studies on the symptomatology, diagnosis, molecular genetic characteristics of ATTR-amyloidosis and the most common forms of the disease with the predominant involvement of peripheral nerves and the heart, as well as the kidneys, gastrointestinal tract, and eyes is presented. The international consensus recommendations for the diagnosis of suspected ATTR-amyloidosis using modern methods that facilitate early and accurate diagnosis are discussed. The reasons and the most frequent misdiagnoses of ATTR-amyloidosis, which also lead to a delay in the timely appointment of therapy, are considered. Molecular genetic testing should be considered early in the evaluation of a patient with unexplained peripheral neuropathy and cardiomyopathy. A diagnostic algorithm based on the initial symptoms and manifestations of the cardiovascular and nervous systems facilitates the identification of a patient with clinical suspicion of ATTR-amyloidosis by the general practitioner. Early diagnosis is critically important for patients with ATTR polyneuropathy, since the early prescription of Vyndaqel (tafamidis), registered in the Russian Federation in 2017, allows a significant clinical effect to be obtained. Timely administration of Vyndaqel significantly slows down the progression of the disease, improves the prognosis and quality of life in patients with ATTR polyneuropathy
ΠΠ΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π°: ΠΎΠ±ΡΠΈΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΊ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
While compression neuropathies of the nerves of the lower limbs are not a common pathology, peroneal nerve neuropathy is the most common of them. Peroneal nerve compression most commonly occurs at or around the head of the fibula, but can also occur in the lower leg, ankle, or foot. Neurophysiological and neuroimaging methods are effective in diagnosing peroneal nerve compression and determining the type of damage. The first line of therapy is lifestyle modification, avoidance of compressive postures, ankle joint orthotics, treatment of knee joint instability when detected, kinesiotherapy. An important role in the correction of symptoms is played using anticholinesterase drugs, the effectiveness of which in diseases of peripheral nervous system has been shown in a number of domestic studies. If conservative treatment fails, surgical treatment is recommended. The diagnosis of peroneal neuropathy is associated with a good prognosis and most patients experience complete recovery of nerve function.ΠΠ΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠΉ ΠΈΠ· ΠΏΠ΅ΡΠ΅ΡΠ½Ρ ΠΊΠΎΠΌΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΡ
Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΉ Π½Π΅ΡΠ²ΠΎΠ² Π½ΠΈΠΆΠ½ΠΈΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ. ΠΠΎΠΌΠΏΡΠ΅ΡΡΠΈΡ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° ΡΠ°ΡΠ΅ Π²ΡΠ΅Π³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡ Π½Π° ΡΡΠΎΠ²Π½Π΅ Π³ΠΎΠ»ΠΎΠ²ΠΊΠΈ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠΈ, Π½ΠΎ ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΠΆΠ΅Ρ Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡΡ Π² ΠΎΠ±Π»Π°ΡΡΠΈ Π³ΠΎΠ»Π΅Π½ΠΈ, Π»ΠΎΠ΄ΡΠΆΠΊΠΈ ΠΈΠ»ΠΈ Π½Π° ΡΡΠΎΠΏΠ΅. ΠΠ΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π½Π΅ΠΉΡΠΎΠ²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½Ρ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΊΠΎΠΌΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ ΡΠΈΠΏΠ° ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ. Π’Π΅ΡΠ°ΠΏΠΈΠ΅ΠΉ 1βΠΉ Π»ΠΈΠ½ΠΈΠΈ ΡΠ²Π»ΡΡΡΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΎΠ±ΡΠ°Π·Π° ΠΆΠΈΠ·Π½ΠΈ, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΊΠΎΠΌΠΏΡΠΈΠΌΠΈΡΡΡΡΠΈΡ
ΠΏΠΎΠ·, ΠΎΡΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π³ΠΎΠ»Π΅Π½ΠΎΡΡΠΎΠΏΠ½ΠΎΠ³ΠΎ ΡΡΡΡΠ°Π²Π°, ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ Π½Π΅ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΡΡΠ°Π²Π° ΠΏΡΠΈ Π΅Π΅ Π½Π°Π»ΠΈΡΠΈΠΈ, ΠΊΠΈΠ½Π΅Π·ΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ. ΠΠ°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΈΠ³ΡΠ°Π΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΡΡΠΈΡ
Ρ
ΠΎΠ»ΠΈΠ½ΡΡΡΠ΅ΡΠ°Π·Ρ, ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΡΠΎΡΡΡ
ΠΏΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π±ΡΠ»Π° ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° Π² ΡΡΠ΄Π΅ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΡΠΎΠ³Π½ΠΎΠ· Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ ΠΌΠ°Π»ΠΎΠ±Π΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ, ΠΈ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΠΏΠΎΠ»Π½ΠΎΠ΅ ΠΈΠ»ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΠΎΠ΅ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ Π½Π΅ΡΠ²Π°. ΠΡΠΈ Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΊΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½Ρ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ
Π‘ΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π°ΡΠΈΠΏΠΈΡΠ½ΡΡ ΡΠΎΡΠΌ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ: ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π·Π° 8 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Π±Π΅Π· ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Introduction. Atypical variants of chronic inflammatory demyelinating polyneuropathy are marked by its clinical heterogeneity and variable disease course.Aim of the study. To describe clinical, anamnestic and neurophysiological features of patients with atypical variants of chronic inflammatory demyelinating polyneuropathy, characterized by benign disease course, minimal motor involvement and not required pathogenic therapy.Materials and methods. 8 patients (7 men (87 %) and 1 woman (13 %) at the age of 52β77 years) with atypical variants of chronic inflammatory demyelinating polyneuropathy were analyzed: 5 patients (62.5 %) with asymmetric variant β multifocal acquired demyelinating sensorimotor neuropathy and 3 patients (37.5 %) with sensory variant. All patients were observed at the Research Center of Neurology for the period of 2016β 2019. In each patient the proper clinical and laboratory evaluation was performed along with nerve conduction study and nerve ultrasound.Results. The disease duration at the time of first visit was 1β8 years. By INCAT disability score 3 (37.5 %) patients had 0 points (normal), 3 (37.5 %) patients β 1 point and 1 patient had 2 (25 %) points. Nerve conduction study showed multifocal, asymmetric demyelinating changes in motor nerves. For the whole period of observation all patients were stable, so no one required pathogenic therapy.Conclusion. Chronic inflammatory demyelinating polyneuropathy is a clinically heterogeneous disorder, required clinical suspicion in all patients over 50 years with features of multiple nerve involvement; nerve conduction study helps to detect typical changes, including subclinical ones. The primary strategy of management typical and atypical disease variants in stable course and minimal symptoms is a case follow-up with precise assessment of advantages and disadvantages of pathogenic therapy.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΡΠΈΠΏΠΈΡΠ½ΡΠ΅ ΡΠΎΡΠΌΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ ΠΈ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π°Π½Π°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Ρ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΈΠ»ΠΈ Π±Π΅Π· Π½ΠΈΡ
, Π½Π΅ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ 8 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (7 ΠΌΡΠΆΡΠΈΠ½ (87 %) ΠΈ 1 ΠΆΠ΅Π½ΡΠΈΠ½Π° (13 %) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 52 Π΄ΠΎ 77 Π»Π΅Ρ) Ρ Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ: 5 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (62,5 %) Ρ Π°ΡΠΈΠΌΠΌΠ΅ΡΡΠΈΡΠ½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ β ΠΌΡΠ»ΡΡΠΈΡΠΎΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½Π½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΡΠ΅Π½ΡΠΎΠΌΠΎΡΠΎΡΠ½ΠΎΠΉ Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ ΠΈ 3 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° (37,5 %) Ρ ΡΠ΅Π½ΡΠΎΡΠ½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ, ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° Π±Π°Π·Π΅ Π¦Π΅Π½ΡΡΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π€ΠΠΠΠ£ Β«ΠΠ°ΡΡΠ½ΡΠΉ ΡΠ΅Π½ΡΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΠΈΒ» Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2016 ΠΏΠΎ 2019 Π³. ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π°Π½Π°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡ, ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π΅ΡΠ²ΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠΌΠΎΡΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° ΠΎΡ 1 Π΄ΠΎ 8 Π»Π΅Ρ. ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ INCAT 3 (37,5 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΈΠΌΠ΅Π»ΠΈ ΡΡΠΌΠΌΠ°ΡΠ½ΡΠΉ Π±Π°Π»Π» 0 (Π½ΠΎΡΠΌΠ°), 3 (37,5 %) β ΠΏΠΎ 1 Π±Π°Π»Π»Ρ Π² ΡΡΠΊΠ°Ρ
ΠΈΠ»ΠΈ Π½ΠΎΠ³Π°Ρ
ΠΈ Π»ΠΈΡΡ Ρ 1 (25 %) β ΡΡΠΌΠΌΠ°ΡΠ½ΡΠΉ Π±Π°Π»Π» ΡΠΎΡΡΠ°Π²ΠΈΠ» 2 (ΠΏΠΎ 1 Π±Π°Π»Π»Ρ Π² ΡΡΠΊΠ°Ρ
ΠΈ Π½ΠΎΠ³Π°Ρ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π½Π΅ΡΠ²ΠΎΠ² Π²ΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
Π²ΡΡΠ²ΠΈΠ»Π° ΠΌΡΠ»ΡΡΠΈΡΠΎΠΊΠ°Π»ΡΠ½ΡΠ΅ Π°ΡΠΈΠΌΠΌΠ΅ΡΡΠΈΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΠΎ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΌΡ ΡΠΈΠΏΡ. ΠΠ° Π²Π΅ΡΡ ΡΡΠΎΠΊ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΡΠ°Π²Π°Π»ΠΎΡΡ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΡΠΌ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠ³ΠΎ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΈΡΠΈΡΠ° ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ Π½ΠΈ ΠΎΠ΄Π½ΠΎΠΌΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π½Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ°Ρ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ β Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΠ΅ ΠΏΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Π΅ ΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ Π±ΡΡΡ Π½Π°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΡΠΌ ΠΏΡΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΡΠ°ΡΡΠ΅ 50 Π»Π΅Ρ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎΠΉ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π΅ΡΠ²ΠΎΠ²; ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π²ΡΡΠ²ΠΈΡΡ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΡΠ±ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅. ΠΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΎΠΉ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ ΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΡΡ
ΡΠΎΡΠΌΠ°Ρ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΡΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ ΠΏΡΠΈ ΡΠ°Π·ΡΠΌΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΠΈ ΠΏΠΎΠ»ΡΠ·Ρ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Features of high-dose intravenous immunotherapy administration in patients with reduced IgA level in neurological practice: literature review and description of a clinical case
Intravenous high-dose immunotherapy is one of the highly effective proven treatments for a number of autoimmune diseases of the nervous system. Nowadays there is enough knowledge about the spectrum of side effects and approaches to their prevention and monitoring. Most of them are leveled by improving the technology of the production process, but anaphylactic reactions remain one of the uncontrolled, albeit rare, undesirable reactions. The development of allergic reactions is associated with the presence of antibodies to immunoglobulin class A (IgA) in the patient, which is manifested by a decrease in the level of IgA during routine immunological examination. The article provides a review of the literature on the prevalence of IgA deficiency, its causes. A modern view of the need for routine testing of IgA level before the course of intravenous immunotherapy, approaches to reduce the risk of developing serious adverse reactions in such cases is described. A clinical case of treatment of a patient with chronic inflammatory demyelinating polyneuropathy and a reduced level of IgA is presented
ΠΡΠ°Ρ ΠΈΠ°Π»Π³ΠΈΡ: Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠ΅ ΠΏΡΠΈΡΠΈΠ½Ρ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° (ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ)
This literature review provides a range of neurological and other organic causes of brachialgia. Features of pain syndrome in different medical conditions are described.ΠΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½ΠΎΠΉ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ. ΠΡΠ°Ρ
ΠΈΠ°Π»Π³ΠΈΡ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ Π²Π΅Π΄ΡΡΠ΅Π΅ ΠΌΠ΅ΡΡΠΎ ΡΡΠ΅Π΄ΠΈ ΠΏΡΠΈΡΠΈΠ½ ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΉ ΠΊ Π²ΡΠ°ΡΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΌ ΠΎΠ±Π·ΠΎΡΠ΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΡΠΏΠ΅ΠΊΡΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΡΠΈΠ½ Π±ΡΠ°Ρ
ΠΈΠ°Π»Π³ΠΈΠΈ, ΠΎΠΏΠΈΡΠ°Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ
Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΡ
ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠΈ Π»ΠΈΡΠ΅Π²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π°
In the article we present the results of the retrospective clinico-electrophysiological analysis of 182 patients suffering from the idiopathicΒ neuropathy of the facial nerve (Bell`s palsy). The comparison of the most common electromyographical (ENMG) predictors of outcomes wasΒ made. It was demonstrated that the most sensitive method in the acutest period (less then 5 days) is the level of excitability of the nerve, inΒ the acute period (less then 14 days) β estimation of M-answer amplitude loss, and from the 21st day β the presence of denervation in muscles.Β The most specific electromyographical approach to estimate the therapy efficiency is an analysis of the M-answer amplitude and latency.Β In conclusion, neurologists have the possibility to predict the outcome and to control the therapy efficiency in any period of the disease.Β The correlation dynamics ΓNMG sensitivity settings β NLN on different dates can be used to determine the volume of ΓNMG β the NLNΒ study depending on the timing for the treatment of patients.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠ»Π΅ΠΊΡΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ (ΠΠΠΠ) Π°Π½Π°Π»ΠΈΠ·Π° 182 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ Π»ΠΈΡΠ΅Π²ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° (ΠΠΠ). ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΠΠΠ-ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡΒ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠ² Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΠΠΠ-ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠΌΒ Π² ΠΎΡΡΡΠ΅ΠΉΡΠ΅ΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ (Π΄ΠΎ 5 Π΄Π½Π΅ΠΉ) ΠΠΠ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΡΠΎΠ³Π° Π²ΡΠ·ΡΠ²Π°Π½ΠΈΡ ΠΌΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎΒ ΡΠ΅ΡΠ»Π΅ΠΊΡΠ°; Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ (ΠΎΡ 10 Π΄ΠΎ 14 Π΄Π½Π΅ΠΉ) β ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΏΠ°Π΄Π΅Π½ΠΈΡ Π°ΠΌΠΏΠ»ΠΈΡΡΠ΄Ρ Π-ΠΎΡΠ²Π΅ΡΠ° ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ; Π½Π°ΡΠΈΠ½Π°Ρ Ρ 21 Π΄Π½Ρ β Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π΅Π²ΡΠΎΠ³Π΅Π½Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΠΌΡΡΡΠ°Ρ
. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Β Π΄Π°Π½Π½ΡΡ
ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΉ ΠΎΠ±ΡΠ΅ΠΌ ΠΠΠΠ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠΠ Π½Π° ΡΠ°Π·Π½ΡΡ
ΡΡΠΎΠΊΠ°Ρ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
ΠΠ½ΠΎΠΌΠ°Π»ΠΈΠΈ ΠΈΠ½Π½Π΅ΡΠ²Π°ΡΠΈΠΈ: Π²Π°ΡΠΈΠ°Π½ΡΡ ΠΈ ΡΠΈΠΏΠΈΡΠ½ΡΠ΅ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ
Π ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ ΡΠ΄Π΅Π»Π΅Π½ΠΎ Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌ ΠΈΠ½Π½Π΅ΡΠ²Π°ΡΠΈΠΈ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅Β ΠΏΡΠ°ΠΊΡΠΈΠΊΡΡΡΠ΅ΠΌΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³Ρ ΠΈ Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³Ρ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ΠΈΡΡΡ ΡΡΠ°Π»ΠΊΠΈΠ²Π°ΡΡΡΡ Ρ Π½Π΅ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉΒ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΉ, Π²ΡΡΠ²Π»ΡΠ΅ΠΌΠΎΠΉ ΠΊΠ°ΠΊ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ, ΡΠ°ΠΊ ΠΈ ΠΏΡΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎΒ Π²ΡΡΡΠ΅ΡΠ°ΡΡΠΈΡ
ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ
ΠΌΠ΅ΠΆΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΡΡ
Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·ΠΎΠ² Π΄Π»ΠΈΠ½Π½ΡΡ
Π½Π΅ΡΠ²ΠΎΠ² ΡΡΠΊ ΠΈ Π½ΠΎΠ³. ΠΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»Π΅Π½ΠΎ Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉΒ ΠΊΠ°ΡΡΠΈΠ½Π΅ Π΄Π°Π½Π½ΡΡ
ΠΌΠ΅ΠΆΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΡΡ
ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΉ. ΠΠ°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΉ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ Π½Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½Π½Π΅ΡΠ²Π°ΡΠΈΠΈΒ ΠΏΠΎΠΌΠΎΠΆΠ΅Ρ ΡΠΎΠΊΡΠ°ΡΠΈΡΡ ΠΎΡΠΈΠ±ΠΊΠΈ Π² ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π΅ΠΌΡΡ
Π² Ρ
ΠΎΠ΄Π΅ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΡΠ»ΡΡΡΠΈΡΒ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ ΠΏΡΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π΅ΡΠ²ΠΎΠ², ΡΡΠ°ΡΡΠ²ΡΡΡΠΈΡ
Π² ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π°.Π ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ ΡΠ΄Π΅Π»Π΅Π½ΠΎ Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌ ΠΈΠ½Π½Π΅ΡΠ²Π°ΡΠΈΠΈ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅Β ΠΏΡΠ°ΠΊΡΠΈΠΊΡΡΡΠ΅ΠΌΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³Ρ ΠΈ Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³Ρ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ΠΈΡΡΡ ΡΡΠ°Π»ΠΊΠΈΠ²Π°ΡΡΡΡ Ρ Π½Π΅ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉΒ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΉ, Π²ΡΡΠ²Π»ΡΠ΅ΠΌΠΎΠΉ ΠΊΠ°ΠΊ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ, ΡΠ°ΠΊ ΠΈ ΠΏΡΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎΒ Π²ΡΡΡΠ΅ΡΠ°ΡΡΠΈΡ
ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ
ΠΌΠ΅ΠΆΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΡΡ
Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·ΠΎΠ² Π΄Π»ΠΈΠ½Π½ΡΡ
Π½Π΅ΡΠ²ΠΎΠ² ΡΡΠΊ ΠΈ Π½ΠΎΠ³. ΠΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»Π΅Π½ΠΎ Π½Π΅ΠΉΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉΒ ΠΊΠ°ΡΡΠΈΠ½Π΅ Π΄Π°Π½Π½ΡΡ
ΠΌΠ΅ΠΆΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΡΡ
ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΉ. ΠΠ°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΉ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ Π½Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½Π½Π΅ΡΠ²Π°ΡΠΈΠΈΒ ΠΏΠΎΠΌΠΎΠΆΠ΅Ρ ΡΠΎΠΊΡΠ°ΡΠΈΡΡ ΠΎΡΠΈΠ±ΠΊΠΈ Π² ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π΅ΠΌΡΡ
Π² Ρ
ΠΎΠ΄Π΅ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π΅ΠΉΡΠΎΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΡΠ»ΡΡΡΠΈΡΒ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ ΠΏΡΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π΅ΡΠ²ΠΎΠ², ΡΡΠ°ΡΡΠ²ΡΡΡΠΈΡ
Π² ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π°
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π‘ΠΠ Π² Π ΠΎΡΡΠΈΠΈ: Π°Π½Π°Π»ΠΈΠ· 186 ΡΠ»ΡΡΠ°Π΅Π²
The medical records of 186 patients diagnosed with Guillain-BarrΓ© syndrome (GBS) who had been followed up at the Research Center ofΒ Neurology, Russian Academy of Medical Sciences, in 2000 to 2011 were retrospectively analyzed. Most (65 %) of the patients had severeΒ GBS; 19 % of the patients were on mechanical ventilation (MV) for an average of 21 (13; 48) days.Β The forms of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) (n = 141; 78 %), and axonal variants, such as acuteΒ motor axonal neuropathy (AMAN), acute sensorimotor axonal neuropathy (AMSAN), i. e. AMAN / AMSAN (n = 39; 22 %), were studiedΒ separately. There was a significant difference in the seasonal revalence (p < 0.05). AIDP was encountered evenly throughout the year;Β AMAN / AMSAN occurred in 46 % of cases in summer. AIDP was followed by acute respiratory viral infection in 35 % of cases; diarrhea wasby the axonal forms in 36 % (p < 0.05). The axonal forms ran a severer course than AIDP: MV was performed twice more frequently (33Β and 15 %, respectively); its duration was 6βfold longer: 90 (46; 102) and 15 (10; 21) days (p < 0.05). AMAN / AMSAN was characterized byΒ a severer neurological status and disability in the acute period, as shown by the NIS, MRCss, INCAT, R-ODS, and Barthel scales; theseΒ patients showed a poorer response to pathogenetic therapy (p < 0.05): 59 % with an insufficient effect; 15 % of those with AIDP. After sixΒ years, the majority (84 %) of the patients with AIDP walked alone and only 16 % were assisted. In the same period, less than half of theΒ patients (40 %) with AMAN / AMSAN walked alone and a third (29 %) could move with assistance and almost the same percentage (31 %)Β could not walk.Thus, a number of specific features of GBS were found in a Russian population (equal age and sex distribution; a larger percentage of theΒ axonal forms than in European countries and the United States); however, the most characteristics did not differ from the global data.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ 186 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΠΈΠΉΠ΅Π½Π° βΒ ΠΠ°ΡΡΠ΅ (Π‘ΠΠ), Π½Π°Π±Π»ΡΠ΄Π°Π²ΡΠΈΡ
ΡΡ Π² Π€ΠΠΠ£ Β«ΠΠ°ΡΡΠ½ΡΠΉ ΡΠ΅Π½ΡΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΠΈΒ» Π ΠΠΠ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2000 ΠΏΠΎ 2011 Π³. Π£ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²Β (65 %) Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΡΡΠΆΠ΅Π»ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π‘ΠΠ, ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½Π°Ρ Π²Π΅Π½ΡΠΈΠ»ΡΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
(ΠΠΠ) ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ 19 % Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 21 (13; 48) Π΄Π΅Π½Ρ.ΠΡΠ»ΠΈ ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Ρ ΡΠΎΡΠΌΡ Π‘ΠΠ: ΠΎΡΡΡΠ°Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ°Ρ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ (ΠΠΠΠ) (n = 141; 78 %)Β ΠΈ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ β ΠΎΡΡΡΠ°Ρ ΠΌΠΎΡΠΎΡΠ½Π°Ρ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΡ (ΠΠΠΠ), ΠΎΡΡΡΠ°Ρ ΠΌΠΎΡΠΎΡΠ½ΠΎ-ΡΠ΅Π½ΡΠΎΡΠ½Π°Ρ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΡ (ΠΠ-Π‘ΠΠ), Ρ. Π΅. ΠΠΠΠ / ΠΠΠ‘ΠΠ (n = 39; 22 %). ΠΡΡΠ²Π»Π΅Π½Π° ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠ°Π·Π½ΠΈΡΠ° Π² ΡΠ΅Π·ΠΎΠ½Π½ΠΎΡΡΠΈ (Ρ < 0,05): ΠΠΠΠ Π²ΡΡΡΠ΅ΡΠ°Π»Π°ΡΡ ΡΠ°Π²Π½ΠΎΠΌΠ΅ΡΠ½ΠΎ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π²ΡΠ΅Π³ΠΎ Π³ΠΎΠ΄Π°, ΠΠΠΠ / ΠΠΠ‘ΠΠ Π² 46 % ΡΠ»ΡΡΠ°Π΅Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ°Π»ΠΈ Π»Π΅ΡΠΎΠΌ. Π 35 % ΡΠ»ΡΡΠ°Π΅Π² ΠΠΠΠ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π»Π° ΠΎΡΡΡΠ°ΡΒ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½Π°Ρ Π²ΠΈΡΡΡΠ½Π°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ, Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΡΠΎΡΠΌΠ°ΠΌ β Π΄ΠΈΠ°ΡΠ΅Ρ (36 %) (p < 0,05). ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π»ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΡΠΆΠ΅Π»Π΅Π΅Β ΠΠΠΠ: ΠΠΠ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Π² 2 ΡΠ°Π·Π° ΡΠ°ΡΠ΅ (33 ΠΈ 15 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ), Π΅Π΅ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π±ΡΠ»Π° Π² 6 ΡΠ°Π· Π±ΠΎΠ»ΡΡΠ΅: 90 (46; 102)Β ΠΈ 15 (10; 21) ΡΡΡ (p < 0,05). ΠΡΠΈ ΠΠΠΠ / ΠΠΠ‘ΠΠ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΡΠΆΠ΅Π»Π΅Π΅ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΠ°ΡΡΡ ΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΡ Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠΎ ΡΠΊΠ°Π»Π°ΠΌ NIS, MRCss, INCAT, R-ODS ΠΈ ΠΠ°ΡΡΠ΅Π»Π°, ΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ
ΡΠΆΠ΅ ΠΎΡΠ²Π΅ΡΠ°ΡΡ Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ (Ρ <Β 0,05): 59 % Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ 15 % ΠΏΡΠΈ ΠΠΠΠ. Π§Π΅ΡΠ΅Π· ΠΏΠΎΠ»Π³ΠΎΠ΄Π° Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠΠ (84 %)Β Ρ
ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎ ΠΈ ΡΠΎΠ»ΡΠΊΠΎ 16 % ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠ³Π°Π»ΠΈΡΡ Ρ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΎΠΉ. ΠΡΠΈ ΠΠΠΠ / ΠΠΠ‘ΠΠ Π² ΡΡΠΈ ΠΆΠ΅ ΡΡΠΎΠΊΠΈ ΠΌΠ΅Π½Π΅Π΅ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ
ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎ (40 %), ΡΡΠ΅ΡΡ ΠΌΠΎΠ³Π»ΠΈ ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠ³Π°ΡΡΡΡ Ρ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΎΠΉ (29 %) ΠΈ ΠΏΠΎΡΡΠΈ ΡΡΠΎΠ»ΡΠΊΠΎ ΠΆΠ΅ (31 %) ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡΒ ΠΎΠ±Π΅Π·Π΄Π²ΠΈΠΆΠ΅Π½Ρ.Β Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π²ΡΡΠ²Π»Π΅Π½ ΡΡΠ΄ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π‘ΠΠ Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ (ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΡ ΠΈ ΠΏΠΎΠ»Ρ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎΠ΅, Π±ΠΎΜΠ»ΡΡΠ°Ρ Π΄ΠΎΠ»Ρ Π°ΠΊΡΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΎΡΠΌ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ ΡΡΡΠ°Π½Π°ΠΌΠΈ ΠΠ²ΡΠΎΠΏΡ ΠΈ ΠΠΌΠ΅ΡΠΈΠΊΠΈ), ΠΎΠ΄Π½Π°ΠΊΠΎ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΒ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΎΡ ΠΌΠΈΡΠΎΠ²ΡΡ
Π΄Π°Π½Π½ΡΡ